RESEARKA

Within-corpus tensions are apparent when comparing effect directions and endpoint sensitivity across studies. By contrast, Mansour 2025 found that nanocurcumin supplementation over 16 weeks did not improve pain, neuropathic outcomes, or metabolic cardiovascular markers, with the primary neuropathy endpoint yielding P = 0.787 and other outcomes reported as P > 0.05, though one secondary endpoint reached P = 0.010. Cares 2026, a systematic review examining diet and exercise interventions in pediatric cancer survivors, reported null findings for cardiometabolic disease risk and inflammaging biomarkers, contrasting with the positive clinical RCT evidence from Kattah 2025 and Yaikwawong 2025b. These disagreements suggest that curcumin's cardiometabolic benefits may be context-dependent, varying by population, dose, formulation, and specific endpoint measured.

Citation Support

• source_1 Flensted-Jensen 2025
• source_2 Flensted-Jensen 2025b
• source_3 Xu 2025
• source_4 El-Rakabawy 2025
• source_5 Schonenberger 2025